S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma by Anne S. Tsao, MD, MBA, Ming-Hui Hsieh, MS, Marianna Koczywas, MD, Janet Tu, MD, Jonathan Riess, MD, MS, Tawee Tanvetyanon, MD, Barbara T. Ma, MD, Ying-Qi Zhao, PhD, Mary W. Redman, PhD, Martin J. Edelman, MD, David R. Gandara, MD, Jhanelle E. Gray, MD, Karen L. Kelly, MD

Subjects: Get full text

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, a... by Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers, Hao‐Wen Sim, Jennifer J. Knox, Valeriya Zaborska, Janine Davies, Yoo‐Joung Ko, Eugene Batuyong, Haider Samawi, Winson Y. Cheung, Richard Lee‐Ying

Subjects: Get full text

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl... by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

Subjects: Get full text